A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Olokizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms CREDO 1
- Sponsors R-Pharm
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Planned End Date changed from 1 Sep 2018 to 1 May 2019.
- 02 Mar 2017 Planned primary completion date changed from 1 May 2018 to 1 Jan 2019.